Today Nymox Pharmaceutical Corp (NASDAQ: NYMX) is trading 3.69% higher.

The latest price, as of 12:03:57 est, was $1.26. Nymox has risen $0.045 in trading today.

18,918 shares have exchanged hands.

As of the previous close, Nymox has moved YTD 6.15%. The company is set to release earnings on 2022-05-13.

For technical charts, analysis, and more on Nymox visit the company profile.

About Nymox Pharmaceutical Corp

Nymox Pharmaceutical Corporation specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the rapidly aging male population in developed economies. The Company's lead drug candidate for benign prostatic hyperplasia (BPH) Fexapotide Triflutate (FT) has completed Phase 3 development in more than 70 clinical centers in the United States, involving more than 1700 patients during the entire clinical development program. Currently, the Company will soon be filing for approval in major economies around the world, including the United States and Europe.

To get more information on Nymox Pharmaceutical Corp and to follow the company's latest updates, you can visit the company's profile page here: Nymox Pharmaceutical Corp's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

Will New AT&T, Dish Co-opetition Deal Work: Jeff Kagan

Cisco Down 12% in Premarket Trading Thursday After Top Line Miss and Lower Forecast

Under Armour CEO Patrik Frisk To Step Down in Surprise Announcement

Target Hits 52-Week Low After Missing Badly on First Quarter Earnings

DLocal Posts Record Q1, Fifth Consecutive 100%+ Revenue Growth Quarter

Another Crypto Winter Wipes Out Billions in Market Value

Inflation + Recession = Recipe for Volatility